TCBP | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 0%

Performance

5 Days

-7.30%

1 Month

-51.75%

3 Months

182.58%

6 Months

-73.17%

1 Year

-8.33%

2 Year

-99.73%

Key data

Stock price

$1.65

P/E Ratio

0.00

DAY RANGE

$1.43 - $1.80

EPS

N/A

52 WEEK RANGE

$0.20 - $9.43

52 WEEK CHANGE

-$2.94

MARKET CAP

2.888 M

YIELD

N/A

SHARES OUTSTANDING

518.463 K

DIVIDEND

$0.00

EX-DIVIDEND DATE

02-10-2025

NEXT EARNINGS DATE

N/A

BETA

-1.45

PUBLIC FLOAT

AVERAGE 10 VOLUME

$472,445

AVERAGE 30 VOLUME

$624,342

Company detail

CEO: Bryan Kobel
Region: US
Website: tcbiopharm.com
Employees: 80
IPO year: 2022

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

TC Biopharm (Holdings) Plc focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia.

TCBP - TC BioPharm (Holdings) plc